COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn BHBH FPVFPV FLVFLV PVP-IPI REGNR2 LY-CoVLY RMDRMD
Ivermectin study #26 of 65
11/11 Early treatment study
Krolewiecki et al., SSRN (Preprint)
Antiviral Effect of High-Dose Ivermectin in Adults with COVID-19: A Pilot Randomised, Controlled, Open Label, Multicentre Trial
Source   PDF   Share   Tweet
Viral load RCT finding a concentration dependent antiviral activity of oral high dose ivermectin at a dosing regimen that is well tolerated.
There was no significant difference in viral load reduction between groups overall, but a significant difference in reduction was found in patients with higher median plasma ivermectin levels (72% vs. 42%, p=0.004).
Decay rate was significantly greater in patients with higher median plasma ivermectin levels (0.64 vs. 0.13, p = 0.011).
Mean ivermectin plasma concentration levels showed a positive correlation with viral decay rate (r = 0.46, p = 0.02).
30 ivermectin patients and 15 control patients.
NCT004381884

Krolewiecki et al., 11/11/2020, preprint, 24 authors.
Details of all 65 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit